



BETA DRUGS LIMITED

BDL/PKL/SEC/2024

28th October, 2024

The Manager
National Stock Exchange of India Ltd.
Exchange Plaza, C/1, Block G
Bandra - Kurla Complex, Bandra (East)
Mumbai 400 051

NSE Symbol: BETA

Beta Drugs Limited Earns Forbes Asia "Best Under a Billion" 2024 Award for Third Consecutive Year, Marks Milestone in Global Expansion and Regulatory Compliance.

Beta Drugs has been recognized by Forbes Asia for the third consecutive year as one of the top "Under a Billion" companies in the Asia-Pacific region. This prestigious accolade is a testament to our unwavering commitment to innovation, operational excellence, and dedication to delivering high-quality oncology and supportive care solutions worldwide.

Receiving this award for three consecutive years is a tremendous achievement for our entire team and a validation of the strategic approach driving our growth and resilience in both Indian and international markets.

At Beta Drugs, we have built a strong foundation centered on patient-centricity, quality, and accessibility. We are among the few Indian companies pioneering the development of NDSS formulations to enhance patient convenience and improve treatment effectiveness.

The company has steadily expanded its global footprint to more than 40 countries and is now poised to enter new markets in the CIS, Africa, and Latin America (Latam). Beta Drugs is rapidly progressing towards a broader global presence. The company has already submitted over 200 dossiers and 600 more in the pipeline. Following recent PICS and EAEU approvals, the company has initiated an audit for EuGMP certification, anticipated by the end of this fiscal year. Achieving EuGMP certification will not only affirm our commitment to global quality standards but also open new pathways for Beta Drugs to serve patients in European markets.

Forbes, a globally renowned business publication, annually curates the '200 Best Under a Billion' list to showcase companies that have demonstrated exceptional performance in terms of revenue growth, profitability, and overall business excellence.

This recognition from Forbes serves as a noteworthy milestone in the company's journey, further solidifying its position as a key player in the pharmaceutical industry.

Thanking You
Your's faithfully
For Beta Drugs Ltd.

Rajni Brar
Company Secretary

CIN No.: L24230HP2005PLC028969

Admin. Office : SCO 184, Sector-5, Panchkula-134 114 Haryana (INDIA) Phone: +91-172-2585481-482-483

Registered Office & Works: Vill. Nandpur, Lodhimajra Road, Tehsil. : Baddi, Distt. Solan, H.P. Phone No. : 01795-236196

Website :- www.betadrugslimited.com

E-Mail :- info@betadrugslimited.com